La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Kymera Therapeutics Résultats passés
Passé contrôle des critères 0/6
Kymera Therapeutics's earnings have been declining at an average annual rate of -29.9%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 5.4% per year.
Informations clés
-29.9%
Taux de croissance des bénéfices
64.7%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 17.0% |
| Taux de croissance des recettes | 5.4% |
| Rendement des fonds propres | -23.0% |
| Marge nette | -178.3% |
| Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results
Aug 11
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up
Jul 14Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being
Jun 12We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth
May 03Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith
Mar 21Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43
Feb 25Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking
Feb 17Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up
Dec 29We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully
Nov 06Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts
Aug 31Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Aug 04Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up
May 21We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely
Apr 16Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth
Dec 28Kymera KT-333 gets FDA orphan drug status for blood cancer subtype
Sep 15Kymera initiated at buy at Jefferies on promise in oncology, autoimmune spaces
Aug 15Kymera Therapeutics GAAP EPS of -$0.78 misses by $0.08, revenue of $11.51M misses by $3.46M
Aug 09Ventilation des recettes et des dépenses
Comment Kymera Therapeutics gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | 89 | -158 | 60 | 0 |
| 31 Mar 24 | 79 | -155 | 57 | 0 |
| 31 Dec 23 | 79 | -147 | 55 | 0 |
| 30 Sep 23 | 47 | -167 | 52 | 0 |
| 30 Jun 23 | 52 | -158 | 49 | 0 |
| 31 Mar 23 | 47 | -159 | 46 | 0 |
| 31 Dec 22 | 47 | -155 | 44 | 0 |
| 30 Sep 22 | 46 | -154 | 44 | 0 |
| 30 Jun 22 | 57 | -139 | 44 | 0 |
| 31 Mar 22 | 64 | -124 | 41 | 0 |
| 31 Dec 21 | 73 | -100 | 36 | 0 |
| 30 Sep 21 | 70 | -79 | 30 | 0 |
| 30 Jun 21 | 65 | -58 | 26 | 0 |
| 31 Mar 21 | 49 | -48 | 22 | 0 |
| 31 Dec 20 | 34 | -55 | 18 | 0 |
| 30 Sep 20 | 23 | -53 | 16 | 0 |
| 30 Jun 20 | 9 | -57 | 10 | 0 |
| 31 Mar 20 | 6 | -52 | 9 | 0 |
| 31 Dec 19 | 3 | -41 | 8 | 0 |
Des revenus de qualité: KYMR is currently unprofitable.
Augmentation de la marge bénéficiaire: KYMR is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: KYMR is unprofitable, and losses have increased over the past 5 years at a rate of 29.9% per year.
Accélération de la croissance: Unable to compare KYMR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: KYMR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Rendement des fonds propres
ROE élevé: KYMR has a negative Return on Equity (-23.05%), as it is currently unprofitable.